Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers.
Phung CD, Tran TTT, Yeo BZJ, Prajogo RC, Saudjana E, Yeo EYM, Gao C, Nguyen PHD, Jayasinghe MK, Dang XTT, Lixuan CP, Nguyen TM, Peng B, Le AH, Nguyen TTT, Chan GME, Loh YH, Goh BC, Tam WL, Bonney GK, Luo D, Le MTN.
Phung CD, et al. Among authors: nguyen ttt, nguyen tm.
Theranostics. 2025 Jun 9;15(14):6818-6838. doi: 10.7150/thno.105519. eCollection 2025.
Theranostics. 2025.
PMID: 40585984
Free PMC article.